Healthcares was Foxo Technologies’s largest segment in fiscal 2025, bringing in $16.09M of $16.37M (98%).
| Segment | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Healthcares | — | — | $4.02M | $16.09M |
| Other Operating | $511.00K | — | — | — |
| Life Science Services | — | — | — | $252.50K |
| Labs & Life | — | $145.29K | — | — |
| Labs | — | — | $32.64K | $13.92K |
| Corporate Segment & Other Operating | — | — | — | $15.09K |
| Total | $511.00K | $145.29K | $4.05M | $16.37M |
Foxo Technologies brought in $16.37M from its four segments in fiscal 2025, the year ended December 31, 2025. Foxo Technologies regrouped these segments after fiscal 2024, so the total does not compare directly with that year's $4.05M. Healthcares was the largest at $16.09M (98.3%), ahead of Life Science Services at $252.50K (1.5%) and Corporate Segment & Other Operating at $15.09K (0.1%). The remaining segment, Labs, brought in $13.92K.
Foxo Technologies began breaking out Healthcares in fiscal 2024, Life Science Services in fiscal 2025, Labs in fiscal 2024 and Corporate Segment & Other Operating in fiscal 2025. Foxo Technologies stopped reporting Other Operating ($511.00K in fiscal 2022) and Labs & Life ($145.29K in fiscal 2023) as separate segments.
Epigenetic Biomarker Royalties was Foxo Technologies’s largest revenue line in fiscal 2021, bringing in $85.00K of $120.00K (71%).
| Income Statement Location | FY 2021 |
|---|---|
| Epigenetic Biomarker Royalties | $85.00K |
| Life Insurance Commissions | $35.00K |
| Total | $120.00K |
Foxo Technologies brought in $120.00K from its two revenue lines in fiscal 2021, the year ended December 31, 2021. Epigenetic Biomarker Royalties was the largest at $85.00K (70.8%), ahead of Life Insurance Commissions at $35.00K (29.2%).
Epigenetic Biomarker Services was Foxo Technologies’s largest product and service line in fiscal 2022, bringing in $400.00K of $511.00K (78%).
| Product and Service | FY 2022 |
|---|---|
| Epigenetic Biomarker Services | $400.00K |
| Epigenetic Biomarker Royalties | $83.00K |
| Life Insurance Commissions | $28.00K |
| Total | $511.00K |
Foxo Technologies brought in $511.00K from its three product and service lines in fiscal 2022, the year ended December 31, 2022. Epigenetic Biomarker Services was the largest at $400.00K (78.3%), ahead of Epigenetic Biomarker Royalties at $83.00K (16.2%) and Life Insurance Commissions at $28.00K (5.5%).
Foxo Technologies (FOXO) reports its revenue by segment, by income statement location and by product and service. In fiscal 2025, Healthcares was its largest segment, bringing in $16.09M (98.3% of the total), followed by Life Science Services at $252.50K (1.5%).
Healthcares was Foxo Technologies' largest segment in fiscal 2025, bringing in $16.09M, or 98.3% of the $16.37M total across its four segments.
Epigenetic Biomarker Royalties was Foxo Technologies' largest revenue line in fiscal 2021, bringing in $85.00K, or 70.8% of the $120.00K total across its two revenue lines.
Epigenetic Biomarker Services was Foxo Technologies' largest product and service line in fiscal 2022, bringing in $400.00K, or 78.3% of the $511.00K total across its three product and service lines.
Every figure comes from Foxo Technologies' annual financial filings, as reported. Each line keeps the name Foxo Technologies gives it, and years follow its fiscal calendar.
Foxo Technologies' revenue by segment goes back to fiscal 2022, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.